


AMENDMENTS

In the Claims:

This listing of claims will replace all prior versions, and listings, of claims in this application.

Claims 1-27 (canceled).

Claim 28 (new): A compound (Ia) or (Ib):



wherein:

Ar^1 is selected from the group consisting of pyrimidinyl, pyridazinyl, and pyrazinyl wherein Ar^1 is optionally substituted, on any ring atom capable of substitution, with 1-3 substituents selected from the group consisting of alkyl, substituted alkyl, amino, substituted amino, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic;

R is selected from the group consisting of alkyl, alkoxy, halo, and mono- and dialkyl-amino;

q is an integer from 0 to 2;

R^1 is selected from the group consisting of hydrogen and alkyl;

Y is CH or N;


R^2 is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, and substituted cycloalkenyl;

X is selected from the group consisting of hydroxyl, alkoxy and substituted alkoxy;

and enantiomers, diasteromers or pharmaceutically acceptable salts thereof;

and further wherein the compound of Formula I has a binding affinity to VLA-4 as expressed by an IC₅₀ of about 15μM or less.

Claim 29 (new): A compound (Ia) or (Ib):



wherein:

Ar^1 is pyrimidinyl which is optionally substituted, on any ring atom capable of substitution, with 1-3 substituents selected from the group consisting of alkyl, substituted alkyl,

amino, substituted amino, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic;

R is selected from the group consisting of alkyl, alkoxy, halo, and mono- and dialkyl-amino;

q is an integer from 0 to 2;

R^1 is selected from the group consisting of hydrogen and alkyl;

Y is CH or N;


R^2 is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, and substituted cycloalkenyl;

X is selected from the group consisting of hydroxyl, alkoxy and substituted alkoxy;


and enantiomers, diasteromers or pharmaceutically acceptable salts thereof;

and further wherein the compound of Formula I has a binding affinity to VLA-4 as expressed by an IC₅₀ of about 15μM or less.

Claim 30 (new): A compound (Ia) or (Ib):



(Ia)



(Ib)

wherein:

Ar¹ is pyridazinyl which is optionally substituted, on any ring atom capable of substitution, with 1-3 substituents selected from the group consisting of alkyl, substituted alkyl, amino, substituted amino, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heteroaryl, substituted heteroaryl, heterocyclic and substituted heterocyclic;

R is selected from the group consisting of alkyl, alkoxy, halo, and mono- and dialkyl-amino;

q is an integer from 0 to 2;

R¹ is selected from the group consisting of hydrogen and alkyl;

Y is CH or N;

R² is selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, and substituted cycloalkenyl;

X is selected from the group consisting of hydroxyl, alkoxy and substituted alkoxy; and enantiomers, diasteromers or pharmaceutically acceptable salts thereof; and further wherein the compound of Formula I has a binding affinity to VLA-4 as expressed by an IC₅₀ of about 15μM or less.

Claim 31 (new): The compound according to any of Claims 28, 29 or 30 wherein R¹ is hydrogen.

Claim 32 (new): The compound according to Claim 31 wherein Y is CH.

Claim 33 (new): The compound according to Claim 31 wherein Y is N.

Claim 34 (new): The compound according to Claim 32 wherein X is hydroxy.

Claim 35 (new): The compound according to Claim 33 wherein X is hydroxy.

Claim 36 (new): The compound according to Claim 34 wherein q is zero.

Claim 37 (new): The compound according to Claim 34 wherein q is one and R is alkoxy.

Claim 38 (new): The compound according to Claim 34 wherein q is zero.

Claim 39 (new): The compound according to Claim 34 wherein q is one and R is alkoxy.

Claim 40 (new): A method for treating an inflammatory disease mediated by VLA-4 in a patient, which method comprises administering a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound as in any one of Claims 28-39.

Claim 41 (new): A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound as in any one of Claims 28-39.